HC Wainwright Forecasts Lower Earnings for Benitec Biopharma

Benitec Biopharma Limited (NASDAQ:BNTC) – Equities researchers at HC Wainwright lowered their Q1 2027 earnings per share estimates for Benitec Biopharma in a research report issued on Monday, September 28th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will earn ($0.29) per share for the quarter, down from their prior estimate of ($0.28). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q2 2027 earnings at ($0.32) EPS, Q3 2027 earnings at ($0.35) EPS, Q4 2027 earnings at ($0.38) EPS and FY2027 earnings at ($1.34) EPS.

A number of other brokerages have also recently commented on BNTC. Royal Bank Of Canada raised shares of Benitec Biopharma to an “outperform” rating in a report on Tuesday, September 15th. Wedbush lifted their price target on shares of Benitec Biopharma from $16.00 to $17.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 15th. Citigroup reissued a “market outperform” rating on shares of Benitec Biopharma in a research report on Tuesday, September 15th. Wall Street Zen lowered Benitec Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Benitec Biopharma in a report on Friday, July 17th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Benitec Biopharma Stock Down 4.2%

Shares of NASDAQ:BNTC opened at $9.58 on Wednesday. The stock has a market capitalization of $334.15 million, a PE ratio of -9.78 and a beta of 0.25. The firm’s 50 day moving average price is $12.01 and its 200-day moving average price is $11.94. Benitec Biopharma has a twelve month low of $9.26 and a twelve month high of $16.76.

Benitec Biopharma (NASDAQ:BNTC) last announced its earnings results on Monday, September 14th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.26).

Hedge Funds Weigh In On Benitec Biopharma

Several large investors have recently added to or reduced their stakes in the company. AWM Investment Company Inc. bought a new stake in shares of Benitec Biopharma in the 2nd quarter worth about $2,515,000. Bank of New York Mellon Corp bought a new position in shares of Benitec Biopharma in the 2nd quarter valued at about $804,000. GAMMA Investing LLC lifted its holdings in shares of Benitec Biopharma by 18.7% in the 2nd quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock valued at $107,000 after acquiring an additional 1,256 shares during the last quarter. Bank of America Corp DE grew its position in Benitec Biopharma by 43.3% in the first quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock worth $185,000 after acquiring an additional 5,251 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new position in Benitec Biopharma in the first quarter worth about $186,000. Hedge funds and other institutional investors own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company’s technology is designed to enable long-lasting suppression of disease-causing genes by delivering genetic instructions that produce RNA interference molecules within targeted cells.

Benitec’s lead product candidate is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD), a rare inherited disorder that can cause progressive weakness of the muscles involved in swallowing and eye movement.